Expert consortium comment on FDA report on risk of T-cell malignancy
Drug Discovery World
JANUARY 10, 2024
These therapies, which exhibit substantial long-term side effects, including genotoxicity and an increased predisposition to secondary cancers, have significantly higher rates of subsequent malignancies than the rate reported for patients following CAR-T cell immunotherapies.
Let's personalize your content